Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
1 recherche sur le mot-clé 'Memantine Fragile-X-syndrome Inattention Hyperactivity Social-withdrawal Irritability'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Open-Label Memantine in Fragile X Syndrome / Craig ERICKSON in Journal of Autism and Developmental Disorders, 39-12 (December 2009)
[article]
Titre : Open-Label Memantine in Fragile X Syndrome Type de document : Texte imprimé et/ou numérique Auteurs : Craig ERICKSON, Auteur ; Christopher J. MCDOUGLE, Auteur ; Jennifer E. MULLETT, Auteur Année de publication : 2009 Article en page(s) : p.1629-1635 Langues : Anglais (eng) Mots-clés : Memantine Fragile-X-syndrome Inattention Hyperactivity Social-withdrawal Irritability Index. décimale : PER Périodiques Résumé : Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67%) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted. En ligne : http://dx.doi.org/10.1007/s10803-009-0807-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=883
in Journal of Autism and Developmental Disorders > 39-12 (December 2009) . - p.1629-1635[article] Open-Label Memantine in Fragile X Syndrome [Texte imprimé et/ou numérique] / Craig ERICKSON, Auteur ; Christopher J. MCDOUGLE, Auteur ; Jennifer E. MULLETT, Auteur . - 2009 . - p.1629-1635.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 39-12 (December 2009) . - p.1629-1635
Mots-clés : Memantine Fragile-X-syndrome Inattention Hyperactivity Social-withdrawal Irritability Index. décimale : PER Périodiques Résumé : Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67%) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted. En ligne : http://dx.doi.org/10.1007/s10803-009-0807-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=883